Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: A prospective cohort study

Journal of Gastroenterology

Volumn 47, Issue 9, 2012, Pages 1030-1035

  Hidaka, Hisashi ^a   Nakazawa, Takahide ^a   Kaneko, Toru ^a   Minamino, Tsutomu ^a   Takada, Juichi ^a   Tanaka, Yoshiaki ^a   Okuwaki, Yusuke ^a   Watanabe, Masaaki ^a   Shibuya, Akitaka ^a   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Congestion index; Duplex Doppler ultrasonography; Portal hypertension

Indexed keywords

SORAFENIB;

ADVANCED CANCER; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; CONGESTION INDEX; CONSCIOUSNESS DISORDER; DOPPLER DEVICE; DOPPLER ECHOGRAPHY; DRUG MECHANISM; FEMALE; FLAPPING TREMOR; HAND FOOT SYNDROME; HEPATOBILIARY PARAMETERS; HUMAN; HYPERAMMONEMIA; HYPERTENSION; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; MALE; OPEN STUDY; PORTAL VEIN BLOOD FLOW; PORTAL VENOUS AREA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEMODYNAMICS; HUMANS; LIVER; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84867582939     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0563-6     Document Type: Article

References (13)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Bland JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
2. Cheng AL, Kang YK, Chen Z, Tasao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
3. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245-56.
4. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding - unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008;47:1764-72.
5. Perelló A, Escorsell A, Bru C, Gilabert R, Moitinho E, Garcia- Pagan JC, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30:1393-7.
6. Sabba C, Merkel C, Zoli M, Ferraioli G, Gaiani S, Sacerdoti D, et al. Interobserver and interequipment variability of echo- Doppler examination of the portal vein: effect of a cooperative training program. Hepatology. 1995;21:428-33.
7. Bolognesi M, Sacerdoti D, Merkel C, Gerunda G, Maffei-Faccioli A, Angeli P, et al. Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Hepatology. 1996;23:1035-40.
8. Moriyasu F, Nishida O, Ban N, Nakamura T, Sakai M, Miyake T, et al. "Congestion index" of the portal vein. Am J Roentgenol. 1986;146:735-9.
9. The Liver Cancer Study Group of Japan. The general rules of the clinical and pathological study of primary liver cancer. 2nd ed. Tokyo: Kanehara; 2003.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
11. Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS ONE. 2011;6:e16978.
12. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. 2009;51:865-73.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.